CA 19-9 (gastrointestinal cancer)
CA 19-9 is a tumour marker used mainly to monitor pancreatic cancer, but also other cancers, especially of the digestive system (bowel, stomach, liver and bile ducts). It is recommended for following the course of the disease, detecting recurrence and assessing the response to treatment.
Preparation and sampling
- Preparation
- Guide to preparing for tests
- Sample
- Blood
- Results available in
- 1 working day
- Where it is done
- All laboratories and map
Description
About the test
CA 19-9 (carbohydrate antigen 19-9) is a glycoprotein made in small amounts by the cells lining the ducts of the pancreas and the bile ducts, and by the lining of the stomach and bowel. Healthy people have low levels in their blood.
Some tumours, above all pancreatic cancer and bile duct cancer, release larger amounts of CA 19-9 into the blood. The marker is therefore used mainly to monitor pancreatic cancer, and it can also be raised in bowel, stomach and liver cancer.
CA 19-9 is not a screening test for cancer in people without symptoms. It can be raised in non-cancerous conditions such as blocked bile flow caused by gallstones or a narrowed bile duct, inflammation of the pancreas (pancreatitis) and liver disease, and a normal value does not rule out a tumour, especially at an early stage.
About 5–10% of people cannot produce CA 19-9 because of an inherited blood group characteristic (the Lewis-negative type). Their level stays low even when a tumour is present, so the marker is of no use for them.
When the disease is being monitored, the change in values over time matters more than a single result.
When it is recommended
- establishing a baseline value before treatment of pancreatic cancer or other digestive cancers;
- monitoring the response to surgery, chemotherapy or other treatment;
- follow-up after treatment, to detect recurrence or progression of the disease;
- as an additional test alongside imaging (ultrasound, CT, MRI) when a tumour of the pancreas or bile ducts is suspected – not as a stand-alone diagnostic test.
Preparation
- No special preparation is needed for the CA 19-9 test itself. If you are having other blood tests on the same day, follow the general rule: blood is taken in the morning, between 7 and 10 a.m., after 12 hours of fasting, and you may drink water as usual.
- Tell your doctor about your diagnosis and when you had surgery, chemotherapy or other treatment.
- Tell your doctor if you have gallbladder or pancreas problems or have recently had jaundice, as these can raise CA 19-9.
- If you take biotin (vitamin B7, common in hair and nail supplements), tell the laboratory: in high doses it can change the results of some immunoassays. With high doses a break is needed, usually 2–3 days.
- For monitoring over time, it is best to have the test done by the same method, ideally in the same laboratory.
- Do not stop prescribed treatment on your own.
Sample
Venous blood.
Reference values
For orientation, the upper reference limit is most often 37 U/mL; with some methods it is lower.
Values obtained by different methods cannot always be compared directly.
Reference values depend on the method and the laboratory; the values printed on your report apply to your result.
Interpreting the results
High values may be seen in:
- pancreatic cancer;
- cancer of the bile ducts and gallbladder;
- stomach, bowel and liver cancer;
- some other tumours (e.g. certain ovarian tumours);
- non-cancerous conditions: blocked bile flow (gallstones or a narrowed bile duct), inflammation of the bile ducts, acute or chronic pancreatitis, hepatitis and cirrhosis of the liver.
Very high values are more often seen with cancer, but blocked bile flow can also cause very high values. For this reason, in jaundice or bile duct inflammation the test is usually repeated once the problem has been resolved.
In people with known cancer, a fall after treatment may indicate a good response, while a rise on successive measurements may indicate recurrence or progression, which has to be confirmed by other investigations, above all imaging.
A value within the reference range does not rule out cancer: in early stages the marker is often not raised, and in Lewis-negative people it stays low regardless of the disease.
Your doctor interprets the result together with your symptoms and other findings.
What can affect the result
- blocked bile flow and inflammation of the bile ducts;
- pancreatitis and liver disease;
- the Lewis-negative blood group type (the marker is not produced);
- timing of the sample in relation to surgery or other treatment;
- differences between the methods and reagents used by laboratories;
- high doses of biotin, depending on the method;
- heterophile antibodies and other interference with immunoassays.
Related tests
- CEA (carcinoembryonic antigen) – another marker used in digestive tumours;
- CA 125 and other tumour markers – depending on the type of tumour;
- Bilirubin, ALT, AST, alkaline phosphatase, GGT – to assess liver function and detect blocked bile flow;
- Amylase and lipase – to assess inflammation of the pancreas;
- Abdominal ultrasound, CT or MRI, endoscopic ultrasound – to detect and monitor changes in the pancreas and bile ducts;
- Histopathology – needed to confirm the diagnosis.
Frequently ordered together
How to order tests online?
Choose the tests you need and add them to your cart. Use the site search to find the tests you want more easily.
Payment method:
- Online – payment uses 3D-Secure, a secure authentication protocol that minimises the risk of fraud.
- At the laboratory – order your tests online and pay for them when you come to the laboratory.
After payment, you will receive an email confirming your order, with details of how to prepare for sampling. From then on, you can go to the Sante laboratory you chose when ordering your tests and have your samples taken.